Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00298766 · ClinicalTrials.gov registry record · Phase 1
Open-Label Phase 1/2 Study of VELCADE for Injection in Patients With Light-chain (AL)-Amyloidosis
A Phase 1 study, sponsored by Millennium Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 70
- Enrollment target
NCT00298766 is a Phase 1 study that has completed, run by Millennium Pharmaceuticals. The registered enrollment target is 70 participants.
The verdict
NCT00298766, a Phase 1 study, has completed, sponsored by Millennium Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 70 participants
- Enrollment target
Study Summary
This is a phase 1/2 open-label, dose-escalation study investigating single-agent therapy with VELCADE in patients with previously treated systemic AL-amyloidosis who require further treatment.
Interventions
- DRUG VELCADE
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2005-06 |
| Est. Completion | 2009-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00298766
The ClinicalTrials.gov registry entry for NCT00298766 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 70 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Millennium Pharmaceuticals, which has 135 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which VELCADE is the first listed.
NCT00298766 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00298766 about?
NCT00298766 is a clinical study titled "Open-Label Phase 1/2 Study of VELCADE for Injection in Patients With Light-chain (AL)-Amyloidosis". This is a phase 1/2 open-label, dose-escalation study investigating single-agent therapy with VELCADE in patients with previously treated systemic AL-amyloidosis who require further treatment.
What is the current status of trial NCT00298766?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 70 participants. The study started on 2005-06. Estimated completion is 2009-09.
What interventions are being tested in trial NCT00298766?
The interventions under investigation include: VELCADE (DRUG).
Who is sponsoring clinical trial NCT00298766?
This trial is sponsored by Millennium Pharmaceuticals, which has 135 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.